Literature DB >> 19336440

Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study.

Lin Zhang1, Junling Chen, Yasun Wang, Fangming Ren, Wen Yu, Linan Cheng.   

Abstract

BACKGROUND: Levonorgestrel (LNG), as a dedicated emergency contraception (EC) product, has been available over-the-counter in China for 10 years. Until now, only a small number of deliveries after LNG-EC failure have been documented.
METHODS: This study was a prospective comparative cohort study. A group of 332 pregnant women who had used LNG-EC during the conception cycle was recruited, and matched to a group of 332 pregnant women without the exposure to LNG. Congenital malformations, perinatal complications and delivery circumstances were investigated in this study.
RESULTS: There were 31 pregnant women in the study group and 28 in the comparison group miscarried within 14 weeks of gestation. In the study and comparison groups, four malformations were found in each group. In the study group, both birthweight (3416 versus 3345 g, P = 0.040) and the sex ratio of birth (boys/girls, 1.14 versus 0.90, P = 0.153) were higher than in the comparison group. There were no statistically significant differences in the incidence of miscarriage or malformation or in the neonatal outcome between the two groups.
CONCLUSIONS: There was no association between the use of LNG-EC pills and the risk of major congenital malformations, pregnancy complications or any other adverse pregnancy outcomes in our study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336440     DOI: 10.1093/humrep/dep076

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  11 in total

1.  Hormonal contraception--what kind, when, and for whom?

Authors:  Inka Wiegratz; Christian J Thaler
Journal:  Dtsch Arztebl Int       Date:  2011-07-18       Impact factor: 5.594

2.  Emergency contraception.

Authors:  Dk Katzman; D Taddeo
Journal:  Paediatr Child Health       Date:  2010-07       Impact factor: 2.253

Review 3.  Emergency contraception review: evidence-based recommendations for clinicians.

Authors:  Kelly Cleland; Elizabeth G Raymond; Elizabeth Westley; James Trussell
Journal:  Clin Obstet Gynecol       Date:  2014-12       Impact factor: 2.190

4.  Emergency contraception: potential role of ulipristal acetate.

Authors:  Kristina Gemzell-Danielsson; Chun-Xia Meng
Journal:  Int J Womens Health       Date:  2010-08-09

Review 5.  Emerging options for emergency contraception.

Authors:  Atsuko Koyama; Laura Hagopian; Judith Linden
Journal:  Clin Med Insights Reprod Health       Date:  2013-02-18

Review 6.  Emergency contraception - potential for women's health.

Authors:  Suneeta Mittal
Journal:  Indian J Med Res       Date:  2014-11       Impact factor: 2.375

Review 7.  Clinical Pharmacology of Hormonal Emergency Contraceptive Pills.

Authors:  Celia M J Matyanga; Blessing Dzingirai
Journal:  Int J Reprod Med       Date:  2018-10-04

8.  Expressions of candidate molecules in the human fallopian tube and chorionic villi of tubal pregnancy exposed to levonorgestrel emergency contraception.

Authors:  Changxiao Huang; Mei Zhang; Chunxia Meng; Wei Shi; Lulu Sun; Jian Zhang
Journal:  Reprod Biol Endocrinol       Date:  2013-05-20       Impact factor: 5.211

Review 9.  A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception.

Authors:  Mohammad Shohel; Mohammad Mahfuzur Rahman; Asif Zaman; Mir Muhammad Nasir Uddin; Md Mamun Al-Amin; Hasan Mahmud Reza
Journal:  BMC Womens Health       Date:  2014-04-04       Impact factor: 2.809

10.  Association between knowledge about levonorgestrel emergency contraception and the risk of ectopic pregnancy following levonorgestrel emergency contraception failure: a comparative survey.

Authors:  Duo Zhang; Ming-Xing Yan; Jue Ma; Wei Xia; Rui-Hong Xue; Jing Sun; Jian Zhang
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-08       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.